Drugs / SHPL-49
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06202378 | Dec 2023 → Nov 2024 | ischemic stroke | Shanghai Hutchison Pharmaceuticals Limited | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07241520 | Dec 2025 → Jun 2027 expected | ischemic stroke | Shanghai Hutchison Pharmaceuticals Limited | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHPL-49 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06202378 ↗ |
| Route | Intravenous | “will be administered as a 30-minute intravenous infusion” NCT07241520 ↗ |